KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BeOne Medicines (ONC) Invested Capital (2016 - 2025)

BeOne Medicines (ONC) has disclosed Invested Capital for 11 consecutive years, with $5.2 billion as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital rose 54.45% to $5.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $5.2 billion, a 54.45% increase, with the full-year FY2025 number at $5.2 billion, up 54.45% from a year prior.
  • Invested Capital was $5.2 billion for Q4 2025 at BeOne Medicines, up from $4.2 billion in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $6.6 billion in Q4 2021 to a low of $3.4 billion in Q3 2021.
  • A 5-year average of $4.4 billion and a median of $4.2 billion in 2024 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: soared 56.04% in 2021, then crashed 31.9% in 2023.
  • BeOne Medicines' Invested Capital stood at $6.6 billion in 2021, then crashed by 30.9% to $4.5 billion in 2022, then decreased by 21.97% to $3.5 billion in 2023, then fell by 4.86% to $3.4 billion in 2024, then surged by 54.45% to $5.2 billion in 2025.
  • Per Business Quant, the three most recent readings for ONC's Invested Capital are $5.2 billion (Q4 2025), $4.2 billion (Q3 2025), and $4.6 billion (Q2 2025).